314 related articles for article (PubMed ID: 30365473)
21. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
22. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma.
Pollom EL; Bui TT; Chang AL; Colevas AD; Hara WY
JAMA Dermatol; 2015 Sep; 151(9):998-1001. PubMed ID: 25874733
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma.
González AR; Etchichury D; Gil ME; Del Aguila R
Ophthalmic Plast Reconstr Surg; 2019; 35(1):56-61. PubMed ID: 30444747
[TBL] [Abstract][Full Text] [Related]
24. Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.
Bayers S; Kapp DL; Beer KR; Slavin B
J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s147-50. PubMed ID: 24085060
[TBL] [Abstract][Full Text] [Related]
25. Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
Sekulic A; Yoo S; Kudchadkar R; Guillen J; Rogers G; Chang ALS; Guenthner S; Raskin B; Dawson K; Mun Y; Chu L; McKenna E; Lacouture M
PLoS One; 2022; 17(1):e0262151. PubMed ID: 35030185
[TBL] [Abstract][Full Text] [Related]
26. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
27. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas.
Sobanko JF; Okman J; Miller C
J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s154-5. PubMed ID: 24085062
[TBL] [Abstract][Full Text] [Related]
28. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib.
Bhutani T; Abrouk M; Sima CS; Sadetsky N; Hou J; Caro I; Chren MM; Arron ST
J Am Acad Dermatol; 2017 Oct; 77(4):713-718. PubMed ID: 28780365
[TBL] [Abstract][Full Text] [Related]
29. Periocular Basal Cell Carcinoma Predictors for Recurrence and Infiltration of the Orbit.
Furdova A; Lukacko P
J Craniofac Surg; 2017 Jan; 28(1):e84-e87. PubMed ID: 27906855
[TBL] [Abstract][Full Text] [Related]
30. Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.
Kahana A; Unsworth SP; Andrews CA; Chan MP; Bresler SC; Bichakjian CK; Durham AB; Demirci H; Elner VM; Nelson CC; Kim DS; Joseph SS; Swiecicki PL; Worden FP
Oncologist; 2021 Jul; 26(7):e1240-e1249. PubMed ID: 33988881
[TBL] [Abstract][Full Text] [Related]
31. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
32. [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
Keserü M; Green S; Dulz S
Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752
[No Abstract] [Full Text] [Related]
33. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
34. Experience With Vismodegib in the Treatment of Advanced Basal Cell Carcinoma at a Cancer Center.
Bernia E; Llombart B; Serra-Guillén C; Bancalari B; Nagore E; Requena C; Calomarde L; Diago A; Lavernia J; Traves V; Guillén C; Sanmartín O
Actas Dermosifiliogr (Engl Ed); 2018 Nov; 109(9):813-820. PubMed ID: 30055751
[TBL] [Abstract][Full Text] [Related]
35. Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma.
Lavasidis G; Tzamalis A; Tsinopoulos I; Ziakas N
Cancer Treat Res Commun; 2024; 39():100796. PubMed ID: 38367414
[TBL] [Abstract][Full Text] [Related]
36. Histologic Changes During Treatment With Vismodegib in Locally Advanced Basal Cell Carcinoma: A Series of 19 Cases.
Bancalari B; Llombart B; Serra-Guillén C; Bernia E; Requena C; Nagore E; Traves V; Calomarde L; Diago A; Guillén C; Sanmartín O
Am J Dermatopathol; 2019 Oct; 41(10):711-717. PubMed ID: 31436575
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.
Chang AL; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Orphanet J Rare Dis; 2016 Sep; 11(1):120. PubMed ID: 27581207
[TBL] [Abstract][Full Text] [Related]
38. Vismodegib: in locally advanced or metastatic basal cell carcinoma.
Keating GM
Drugs; 2012 Jul; 72(11):1535-41. PubMed ID: 22788238
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant vismodegib in the management of locally advanced periocular basal cell carcinoma.
Curragh DS; Huilgol SC; Selva D
Eye (Lond); 2021 Oct; 35(10):2740-2745. PubMed ID: 33235336
[TBL] [Abstract][Full Text] [Related]
40. Vismodegib.
Meiss F; Zeiser R
Recent Results Cancer Res; 2014; 201():405-17. PubMed ID: 24756807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
